Evidence map›Paper›PMID 42404435›Full record

ArticleBrain communications2026

Value of synaptic proteins as biomarkers in amyotrophic lateral sclerosis.

Frederik Hobin, Shreyasee Das, Charlotte Lambrechts, Charlotte De Rocker, Jonas Dubin, Fouke Ombelet, Joke De Vocht, Nikita Lamaire, Eugeen Vanmechelen, Koen Poesen and 1 more

Abstract read
In one paragraph

Article in Brain communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Frederik HobinDepartment of Neurology, University Hospitals Leuven, 3000 Leuven, Belgium.ORCID https://orcid.org/0009-0005-2167-5896
Shreyasee DasDepartment of Biomarker Development, Fujirebio Europe NV, 9052 Ghent, Belgium.
Charlotte LambrechtsDepartment of Biomarker Development, Fujirebio Europe NV, 9052 Ghent, Belgium.
Charlotte De RockerDepartment of Biomarker Development, Fujirebio Europe NV, 9052 Ghent, Belgium.
Jonas DubinLaboratory of Molecular Neurobiomarker Research, Department of Neurosciences, Leuven Brain Institute (LBI), KU Leuven, 3000 Leuven, Belgium.
Fouke OmbeletDepartment of Neurology, University Hospitals Leuven, 3000 Leuven, Belgium.
Joke De VochtDepartment of Neurology, University Hospitals Leuven, 3000 Leuven, Belgium.ORCID https://orcid.org/0000-0003-4116-192X
Nikita LamaireDepartment of Neurology, University Hospitals Leuven, 3000 Leuven, Belgium.
Eugeen VanmechelenDepartment of Biomarker Development, Fujirebio Europe NV, 9052 Ghent, Belgium.
Koen PoesenLaboratory of Molecular Neurobiomarker Research, Department of Neurosciences, Leuven Brain Institute (LBI), KU Leuven, 3000 Leuven, Belgium.ORCID https://orcid.org/0000-0001-5290-9476
Philip Van DammeDepartment of Neurology, University Hospitals Leuven, 3000 Leuven, Belgium.ORCID https://orcid.org/0000-0002-4010-2357

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyotrophic lateral sclerosis is a heterogeneous and rapidly progressing neurodegenerative disorder with limited treatment options. Therefore, there is a critical need for biomarkers that capture the diverse pathophysiological mechanisms underlying disease onset and progression. Emerging evidence suggests that synaptic dysfunction is an early disease mechanism in amyotrophic lateral sclerosis. Using homebrew immunoassays, we explored a panel of pre- and post-synaptic proteins in cerebrospinal fluid of patients with amyotrophic lateral sclerosis (

Indexed as

amyotrophic lateral sclerosisbiomarkercerebrospinal fluidprognosissynapse

Identifiers

PMID42404435
PMCPMC13332409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.